Year-end Sale % OFF 
Abstract
BACKGROUND To estimate the cost-effectiveness of carotid stenting (CAS) compared to endarterectomy (CEA) in symptomatic patients. METHODS A cost-utility analysis from the Canadian health system perspective was performed using a Markov analytic model. Clinical estimates were based on a recent meta-analysis. Procedural costs for CAS and CEA were derived from a local cohort. The costs for hospitalization and rehabilitation for minor and major strokes were based on the Burden of Ischemic Stroke (BURST) study. Utility scores were based on SAPPHIRE trial. A Monte Carlo simulation using a hypothetical cohort of 10,000 and sensitivity analyses were performed to investigate the model assumptions and uncertainties. RESULTS CAS was more expensive (incremental cost of $6106.84) and had a lower effectiveness (- 0.12 QALYs). The model was sensitive to the risk of annual death. At a threshold odds ratio (OR) of 0.85, CAS was associated with an incremental cost-effectiveness ratio (ICER) of $32,839.04. Using estimates from SAPPHIRE trial, CAS dominated CEA. When estimates from CREST or EVA-3S trials were used, CEA dominated CAS. Only after simultaneously reducing CAS costs and risks of periprocedural and annual minor strokes, CAS had a favorable ICER. This was achieved at a threshold CAS procedural cost of $4350, a threshold OR of periprocedural minor stroke of 1, and a threshold OR of annual minor stroke of 1.15or less; resulting in an ICER of $577.5. The figure shows CAS cost-effectiveness plane. CONCLUSIONS In this analysis, CAS was associated with higher costs and lower effectiveness compared to CEA in symptomatic carotid stenosis patients. The results were driven by the costs of periprocedural major and minor stroke. The costs associated with MI did not impact the results. For CAS to be more effective, it needs to be performed in patients with longer survival, in patients at a high surgical-risk, or at a lower procedural costs plus lower rates of periprocedural and annual minor strokes.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
